Evidence map›Paper›PMID 41575738›Full record

ArticleMolecular cancer research : MCR2026

Modeling of Capicua Family Fusion Oncoprotein-Driven Cancers Reveals Gene-Specific Functionality.

Cuyler Luck, Yongfeng Luo, Elena Vasileva, Kyle A Jacobs, Julia Riad, Christopher D Macaraig, Rovingaile Kriska M Ponce, James F Amatruda, Ross A Okimoto

Abstract read
In one paragraph

Article in Molecular cancer research : MCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Cuyler LuckBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1150-0057
Yongfeng LuoCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California.ORCID 0000-0001-8765-0273
Elena VasilevaCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California.ORCID 0000-0003-2026-1331
Kyle A JacobsBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4411-7855
Julia RiadDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0009-0009-7481-8079
Christopher D MacaraigDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0009-0001-2723-9252
Rovingaile Kriska M PonceDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-6122-4153
James F AmatrudaCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California.ORCID 0000-0002-9901-2137
Ross A OkimotoDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4467-8476

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Targeting EWSR1-FLI1 through Functional, Structural and Chemical ApproachesU54CA231649 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI AMATRUDA, JAMES F, MCFADDEN, DAVID GLENN · 2019 to 2019
$10.0M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomasR37CA255453 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Ross Okimoto · 2021 to 2026
$2.7M
The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppressionR01CA299039 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Ross Okimoto, Hua E Yu · 2025 to 2026
$1.2M
Leveraging Retained Partner Gene Function to Effectively Target CIC-rearranged Fusion OncoproteinsF31CA287493 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LUCK, CUYLER · 2024 to 2025
$92k
Children's Cancer Research Fund (CCRF)National Cancer Institute (NCI) CA255453National Cancer Institute (NCI) CA287493National Cancer Institute (NCI) P30CA014089National Cancer Institute (NCI) U54CA231649National Institute of General Medical Sciences (NIGMS) T32GM136547-01National Science Foundation Graduate Research Fellowship Program (GRFP) 2038436NCI NIH HHS F31 CA287493NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA299039NCI NIH HHS R37 CA255453NCI NIH HHS U54 CA231649NIDDK NIH HHS P30 DK063720NIGMS NIH HHS T32 GM136547Tobacco-Related Disease Research Program (TRDRP) T33DT6442
6 · The paper itself

Abstract

Clinical divergence between patients harboring Capicua (CIC) rearrangements is frequently observed. For example, the prototypical CIC::DUX4 fusion associates with soft-tissue tumors whereas CIC::NUTM1 fusions typically localize to the central nervous system (brain/spinal cord). The basis for these differences is poorly understood because of a lack of molecular tools. To address this need, we generated patient-informed, synthetic coding sequences for CIC::NUTM1, CIC::LEUTX, and ATXN1::DUX4 and validated them in structure-function studies and in genetic zebrafish models. We found that CIC::NUTM1 drives a transcriptional program distinct from that of CIC::DUX4 because of a C-terminal NUTM1 functional domain, CIC::LEUTX weakly activates CIC target genes through LEUTX transactivation sequences, and ATXN1::DUX4 upregulates CIC target genes via the ATXN1 AXH domain. Our findings indicate that the CIC fusion binding partner may alter overall fusion oncoprotein activity. IMPLICATIONS: These first-generation synthetic tools illuminate partner gene-specific mechanistic biology while providing an unprecedented resource to study CIC-family fusions beyond CIC::DUX4 and allow for the dissection of this rare subgroup of cancers.

Indexed as

NeoplasmsOncogene Proteins, FusionRepressor ProteinsAnimalsHumansZebrafishCIC protein, humanOncogene Proteins, FusionRepressor Proteins

Identifiers

PMID41575738
PMCPMC12930430

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.